Skip to content

Effective of Positive Psychotherapy in patients with moderate to severe depression who are not responding to Escitalopram

Effectiveness of adjuvant Positive Psychotherapy on illness severity and wellbeing in Escitalopram non-responder patients with moderate to severe Depression: A Randomized Control Trial - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/10/074594
Enrollment
54
Registered
2024-10-01
Start date
Unknown
Completion date
Unknown
Last updated
2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F332- Major depressive disorder, recurrent severe without psychotic features Health Condition 2: F331- Major depressive disorder, recurrent, moderate Health Condition 3: F321- Major depressive disorder, singleepisode, moderate Health Condition 4: F322- Major depressive disorder, singleepisode, severe without psychotic features

Interventions

Intervention1: Positive Psychotherapy: Intervention group will receive 10 sessions of positive psychotherapy along with Tablet Fluoxetine 20mg to 40mg once in a day. The intervention will be for a pe

Sponsors

Michelle Melwyn Joel
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Provision of signed and dated informed consent form 2. Clients diagnosed according to ICD-11 criteria for : · 6A70.1 Single Episode Depressive Disorder, Moderate, without psychotic symptoms · 6A70.3 Single Episode Depressive Disorder, Severe, without psychotic symptoms · A71.1 Recurrent Depressive Disorder, Current Episode Moderate, without psychotic symptoms · 6A71.3 Recurrent Depressive Disorder, Current Episode Severe, without psychotic symptoms 3. Age 18 to 50 years 4. Attend AIIMS Bhopal Psychiatry OPD 5. A score of 10 or above on the Patient Health Questionnaire 9 (PHQ-9) 6. Educated at least till 10th standard 7. Participants who are non responders of escitalopram

Exclusion criteria

Exclusion criteria: 1.Women who are pregnant or are breastfeeding or lactating 2. Participants with a history of organicity, epilepsy, or other neurological deficits. 3. Participants with a history of intellectual disability, psychosis, including schizophrenia spectrum disorders or bipolar disorder. 4. Participants planning to move out of the study area during the follow-up period. 5. Participants who do not speak either English or Hindi. 6. Participants who are undergoing psychotherapy for depression at the time of recruitment. 7. Participants at imminent risk for suicide. 8. Participants who have documented non-response to fluoxetine in current or past episodes

Design outcomes

Primary

MeasureTime frame
Illness Severity of Depression using PHQ-9 score. A score less than 10 will show change in illness severityTimepoint: Baseline, 4 weeks, 10 weeks, 1 month post intervention

Secondary

MeasureTime frame
Improvement in Wellbeing using Mental Health Continuum scoreTimepoint: Baseline, 10 weeks

Countries

India

Contacts

Public ContactMichelle Melwyn Joel

AIIMS Bhopal

abhijit.psy@aiimsbhopal.edu.in9279006732

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026